View : 366 Download: 60

Full metadata record

DC Field Value Language
dc.contributor.author이상혁-
dc.contributor.authorCharles Lee-
dc.date.accessioned2019-01-02T16:30:30Z-
dc.date.available2019-01-02T16:30:30Z-
dc.date.issued2018-
dc.identifier.issn1226-3613-
dc.identifier.issn2092-6413-
dc.identifier.otherOAK-23951-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/248133-
dc.description.abstractCancer immunotherapy is a promising way to eliminate tumor cells by using the patient's own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.-
dc.languageEnglish-
dc.publisherNATURE PUBLISHING GROUP-
dc.titleStudying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice-
dc.typeReview-
dc.relation.volume50-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.indexKCI-
dc.relation.journaltitleEXPERIMENTAL AND MOLECULAR MEDICINE-
dc.identifier.doi10.1038/s12276-018-0115-0-
dc.identifier.wosidWOS:000441266700005-
dc.author.googleChoi, Yunsik-
dc.author.googleLee, Sanghyuk-
dc.author.googleKim, Kapyoul-
dc.author.googleKim, Soo-Hyun-
dc.author.googleChung, Yeun-Jun-
dc.author.googleLee, Charles-
dc.contributor.scopusid이상혁(55716450000)-
dc.contributor.scopusidCharles Lee(23980489900)-
dc.date.modifydate20200301081000-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE